158 related articles for article (PubMed ID: 8837167)
1. Assessing a drug's cost-benefits.
Raleigh F
Psychiatr Serv; 1996 Aug; 47(8):877-8. PubMed ID: 8837167
[No Abstract] [Full Text] [Related]
2. Economic and health state utility determinations for schizophrenic patients treated with risperidone or haloperidol.
Chouinard G; Albright PS
J Clin Psychopharmacol; 1997 Aug; 17(4):298-307. PubMed ID: 9241010
[TBL] [Abstract][Full Text] [Related]
3. Cost-benefits of risperidone.
Bilsker D
Psychiatr Serv; 1996 Mar; 47(3):309-10. PubMed ID: 8820560
[No Abstract] [Full Text] [Related]
4. [Cognition and driving in schizophrenic patients under treatment with risperidone vs. haloperidol].
Dittert S; Soyka M; Winter C; Möller HJ
Fortschr Neurol Psychiatr; 1999 Nov; Suppl 2():S70-3. PubMed ID: 10598340
[No Abstract] [Full Text] [Related]
5. A Cost-effectiveness Analysis of Antipsychotics for Treatment of Schizophrenia in Uganda.
Lubinga SJ; Mutamba BB; Nganizi A; Babigumira JB
Appl Health Econ Health Policy; 2015 Oct; 13(5):493-506. PubMed ID: 25958192
[TBL] [Abstract][Full Text] [Related]
6. Cost analysis of the treatment of schizophrenia in the UK. A simulation model comparing olanzapine, risperidone and haloperidol.
Almond S; O'Donnell O
Pharmacoeconomics; 2000 Apr; 17(4):383-9. PubMed ID: 10947493
[TBL] [Abstract][Full Text] [Related]
7. Cost-benefits of new drugs.
Daniel DG; Moseley C; Rosenfield S; Wolf S; Nawroz S
Psychiatr Serv; 1995 Aug; 46(8):835-6. PubMed ID: 7583490
[No Abstract] [Full Text] [Related]
8. Impact of newer antipsychotics on outcomes in schizophrenia.
Keks NA
Clin Ther; 1997; 19(1):148-58; discussion 126-7. PubMed ID: 9083717
[TBL] [Abstract][Full Text] [Related]
9. First generation antipsychotics switch with Risperidone in the treatment of chronic schizophrenic patients.
Popović I; Ravanić D; Popović V; Vladejić S; Stanojević A; Stojanović M
Psychiatr Danub; 2011 Dec; 23(4):384-8. PubMed ID: 22075740
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness and quality of life in psychosis: the pharmacoeconomics of risperidone.
Aronson SM
Clin Ther; 1997; 19(1):139-47; discussion 126-7. PubMed ID: 9083716
[TBL] [Abstract][Full Text] [Related]
11. A cost-effectiveness clinical decision analysis model for schizophrenia.
Palmer CS; Revicki DA; Genduso LA; Hamilton SH; Brown RE
Am J Manag Care; 1998 Mar; 4(3):345-55. PubMed ID: 10178497
[TBL] [Abstract][Full Text] [Related]
12. Negative signs and symptoms secondary to antipsychotics: a double-blind, randomized trial of a single dose of placebo, haloperidol, and risperidone in healthy volunteers.
Artaloytia JF; Arango C; Lahti A; Sanz J; Pascual A; Cubero P; Prieto D; Palomo T
Am J Psychiatry; 2006 Mar; 163(3):488-93. PubMed ID: 16513871
[TBL] [Abstract][Full Text] [Related]
13. A double-blind, randomized study comparing the efficacy and safety of sertindole and risperidone in patients with treatment-resistant schizophrenia.
Kane JM; Potkin SG; Daniel DG; Buckley PF
J Clin Psychiatry; 2011 Feb; 72(2):194-204. PubMed ID: 20673553
[TBL] [Abstract][Full Text] [Related]
14. Future employability, a new approach to cost-effectiveness analysis of antipsychotic therapy.
Ganguly R; Miller LS; Martin BC
Schizophr Res; 2003 Sep; 63(1-2):111-9. PubMed ID: 12892865
[TBL] [Abstract][Full Text] [Related]
15. The relationship of Akathisia with treatment emergent suicidality among patients with first-episode schizophrenia treated with haloperidol or risperidone.
Seemüller F; Lewitzka U; Bauer M; Meyer S; Musil R; Schennach R; Riedel M; Doucette S; Möller HJ
Pharmacopsychiatry; 2012 Nov; 45(7):292-6. PubMed ID: 22614116
[TBL] [Abstract][Full Text] [Related]
16. Economic evaluation of antipsychotic drugs for schizophrenia treatment within the Brazilian Healthcare System.
Lindner LM; Marasciulo AC; Farias MR; Grohs GE
Rev Saude Publica; 2009 Aug; 43 Suppl 1():62-9. PubMed ID: 19669066
[TBL] [Abstract][Full Text] [Related]
17. Risperidone in treatment-refractory schizophrenia.
Wirshing DA; Marshall BD; Green MF; Mintz J; Marder SR; Wirshing WC
Am J Psychiatry; 1999 Sep; 156(9):1374-9. PubMed ID: 10484947
[TBL] [Abstract][Full Text] [Related]
18. Schizophrenia and severe tardive dyskinesia responsive to risperidone.
Kopala LC; Honer WG
J Clin Psychopharmacol; 1994 Dec; 14(6):430-1. PubMed ID: 7533794
[No Abstract] [Full Text] [Related]
19. Symptoms in neuroleptic-naive, first-episode schizophrenia: response to risperidone.
Kopala LC; Fredrikson D; Good KP; Honer WG
Biol Psychiatry; 1996 Feb; 39(4):296-8. PubMed ID: 8645777
[No Abstract] [Full Text] [Related]
20. The treatment of challenging behaviour in intellectual disabilities: cost-effectiveness analysis.
Romeo R; Knapp M; Tyrer P; Crawford M; Oliver-Africano P
J Intellect Disabil Res; 2009 Jul; 53(7):633-43. PubMed ID: 19460067
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
